Literature DB >> 17561233

Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva.

Alexander Olawaiye1, Lisa M Lee, Carolyn Krasner, Neil Horowitz.   

Abstract

BACKGROUND: The purpose of this case report is to describe the first experience with erlotinib (Tarceva) in the treatment of locally advanced vulvar cancer. CASE: Two elderly patients presented with locally advanced vulvar cancer. Surgery was not a suitable method of treatment for either of them because of multiple medical co-morbidities and stage of disease. One patient had disease progression on standard chemoradiation. Erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, was tried in both cases and dramatic responses were observed.
CONCLUSION: Therapy targeted to EGFR may be effective in the treatment of locally advanced vulvar cancer. This new therapeutic approach deserves further evaluation in carefully designed studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561233     DOI: 10.1016/j.ygyno.2007.05.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature.

Authors:  Hanane Inrhaoun; Ibrahim Elghissassi; Maya Gutierrez; Etienne Brain; Hassan Errihani
Journal:  Gynecol Oncol Case Rep       Date:  2012-07-27

2.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

Review 3.  Molecular pathways in vulvar squamous cell carcinoma: implications for target therapeutic strategies.

Authors:  Simona Maria Fragomeni; Frediano Inzani; Anna Fagotti; Luigi Della Corte; Stefano Gentileschi; Luca Tagliaferri; Gian Franco Zannoni; Giovanni Scambia; Giorgia Garganese
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-25       Impact factor: 4.553

Review 4.  Chemotherapy of vulvar cancer: a review.

Authors:  Gunter Deppe; Ismail Mert; Jimmy Belotte; Ira S Winer
Journal:  Wien Klin Wochenschr       Date:  2013-03-22       Impact factor: 1.704

Review 5.  Therapeutic advances in women's cancers.

Authors:  Amy R Carroll; Robert L Coleman; Anil K Sood
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

Review 6.  Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.

Authors:  Riccardo Di Fiore; Sherif Suleiman; Francesca Pentimalli; Sharon A O'Toole; John J O'Leary; Mark P Ward; Neil T Conlon; Maja Sabol; Petar Ozretić; Ayse Elif Erson-Bensan; Nicholas Reed; Antonio Giordano; C Simon Herrington; Jean Calleja-Agius
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 7.  Management of Advanced Squamous Cell Carcinoma of the Vulva.

Authors:  Linda J Rogers
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

8.  Cancer of the vulva: 2021 update.

Authors:  Alexander B Olawaiye; Mauricio A Cuello; Linda J Rogers
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.